8117 Background: WJTOG3405 has proven that chemotherapy-naïve patients with
postoperative recurrent or stage IIIB/IV NSCLC harboring activating EGFR mutation have …

7521 Background: WJTOG3405 met its primary endpoint of progression free survival
(PFS)(9.2 months (mo.) for G vs. 6.3 mo. for CD, hazard ratio (HR) 0.489, 95% confidence …

Background Primary analysis of the phase III study WJTOG 3405 demonstrated superiority of
progression-free survival (PFS) for gefitinib (G) in patients treated with the epidermal growth …

7519 Background: NEJ002 have demonstrated a significant superiority of gefitinib on
progression-free survival compared with CBDCA plus PTX (CP) as the first-line treatment for …

Background NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel
(PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) …

Background Patients with non-small-cell lung cancer harbouring mutations in the epidermal
growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase …

8016 Background: Based on our promising results of phase II studies estimating gefitinib in
NSCLC pts with sensitive EGFR mutations (JCO 2006, BJC 2006), this multicenter phase III …

9005 Background: Although EGFR-TKI alone has been a standard first-line treatment for pts
with advanced NSCLC with EGFR mutations, our phase II study (NEJ005) showed …

Retrospective analysis has shown that activating mutations in exons 18–21 of the epidermal
growth factor receptor (EGFR) gene are a predictor of response to gefitinib. We conducted a …

PURPOSE To investigate the efficacy of gefitinib as an adjuvant therapy for non–small-cell
lung cancer patients with EGFR mutation. PATIENTS AND METHODS IMPACT …